Synthesis of Oxamide-hydrazone Hybrid Derivatives As Potential Anticancer Agents

Overview

Journal Res Pharm Sci

Specialty Chemistry

Date 2023 Feb 27

PMID 36846733

Authors

Mina Dehbid

Raheleh Tahmasvand

Marzieh Tasharofi

Fatemeh Shojaie

Mahmoudreza Aghamaali

Ali Almasirad

Mona Salimi

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Considering various studies implying anticancer activity of the hydrazone and oxamide derivatives through different mechanisms such as kinases and calpain inhibition, herein, we report the synthesis, characterization, and evaluation of the antiproliferative effect of a series of hydrazones bearing oxamide moiety compounds () against a panel of cancer cell lines to explore a novel and promising anticancer agent ().

Experimental Approach: Chemical structures of the synthesized compounds were confirmed by FTIR, H-NMR, C-NMR, and mass spectra. The antiproliferative activity and cell cycle progression of the target compound were investigated using the MTT assay and flow cytometry.

Findings/results: Compound with 2-hydroxybenzylidene structure was found to have a significant anti-proliferative influence on MDA-MB-231 (human adenocarcinoma breast cancer) and 4T1 (mouse mammary tumor) cells as the model of triple-negative breast cancer, with the IC50-72h values of 7.73 ± 1.05 and 1.82 ± 1.14 μM, respectively. Following 72-h incubation with compound , it caused MDA-MB-231 cell death through G1/S cell cycle arrest at high concentrations (12 and 16 μM).

Conclusion And Implications: Conclusively, this study for the first time reports the anti-proliferative efficacy of compound possessing 2-hydroxyphenyl moiety, which may serve as a potent candidate in triple-negative breast cancer treatment.

Citing Articles

In vitro and in vivo activity of a novel oxamide-hydrazone hybrid derivative against triple-negative breast cancer.

Tahmasvand R, Dehghani S, Kooshafar Z, Emami Najafi S, Almasirad A, Salimi M Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(7):5119-5129.

PMID: 38240779 DOI: 10.1007/s00210-023-02931-6.

References

Horiuchi T, Takeda Y, Haginoya N, Miyazaki M, Nagata M, Kitagawa M . Discovery of novel Thieno[2,3-d]pyrimidin-4-yl hydrazone-based cyclin-dependent kinase 4 inhibitors: synthesis, biological evaluation and structure-activity relationships. Chem Pharm Bull (Tokyo). 2011; 59(8):991-1002. DOI: 10.1248/cpb.59.991. View

Lee K, Lee K, Jin C, Lee Y . Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives. Eur J Med Chem. 2008; 44(3):1331-4. DOI: 10.1016/j.ejmech.2008.02.023. View

Cui Z, Li Y, Ling Y, Huang J, Cui J, Wang R . New class of potent antitumor acylhydrazone derivatives containing furan. Eur J Med Chem. 2010; 45(12):5576-84. DOI: 10.1016/j.ejmech.2010.09.007. View

Wu J, Zhang D, Chen L, Li J, Wang J, Ning C . Discovery and mechanism study of SIRT1 activators that promote the deacetylation of fluorophore-labeled substrate. J Med Chem. 2013; 56(3):761-80. DOI: 10.1021/jm301032j. View

Tavakolfar S, Mousavi E, Almasirad A, Amanzadeh A, Atyabi S, Yaghamii P . In Vitro Anticancer Effects of Two New Potent Hydrazide Compounds on Leukemic Cells. Anticancer Agents Med Chem. 2016; 16(12):1646-1651. DOI: 10.2174/1871520616666160404112945. View

DeSantis C, Ma J, Gaudet M, Newman L, Miller K, Sauer A . Breast cancer statistics, 2019. CA Cancer J Clin. 2019; 69(6):438-451. DOI: 10.3322/caac.21583. View

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View

Asadi M, Mohammadi-Khanaposhtani M, Hosseini F, Gholami M, Dehpour A, Amanlou M . Design, synthesis, and evaluation of novel racecadotril-tetrazole-amino acid derivatives as new potent analgesic agents. Res Pharm Sci. 2021; 16(4):341-357. PMC: 8356715. DOI: 10.4103/1735-5362.319573. View

Ma X, Yu H . Global burden of cancer. Yale J Biol Med. 2007; 79(3-4):85-94. PMC: 1994799. View

10.

El-Gammal O, Abu El-Reash G, Ahmed S . Synthesis, spectral characterization, molecular modeling and in vitro antibacterial activity of complexes designed from OO, NO and NN donor Schiff-base ligand [corrected]. Spectrochim Acta A Mol Biomol Spectrosc. 2014; 135:227-40. DOI: 10.1016/j.saa.2014.04.197. View

11.

Wang C, Li Y, Liu T, Wang Z, Zhang Y, Bao K . Design, synthesis and evaluation of antiproliferative and antitubulin activities of 5-methyl-4-aryl-3-(4-arylpiperazine-1-carbonyl)-4H-1,2,4-triazoles. Bioorg Chem. 2020; 104:103909. DOI: 10.1016/j.bioorg.2020.103909. View

12.

Mousavi E, Tavakolfar S, Almasirad A, Kooshafar Z, Dehghani S, Afsharinasab A . In vitro and in vivo assessments of two novel hydrazide compounds against breast cancer as well as mammary tumor cells. Cancer Chemother Pharmacol. 2017; 79(6):1195-1203. DOI: 10.1007/s00280-017-3318-5. View

13.

Nasr T, Bondock S, Rashed H, Fayad W, Youns M, Sakr T . Novel hydrazide-hydrazone and amide substituted coumarin derivatives: Synthesis, cytotoxicity screening, microarray, radiolabeling and in vivo pharmacokinetic studies. Eur J Med Chem. 2018; 151:723-739. DOI: 10.1016/j.ejmech.2018.04.014. View

14.

Yousef T, Abu El-Reash G, Rakha T, El-Ayaan U . First row transition metal complexes of (E)-2-(2-(2-hydroxybenzylidene) hydrazinyl)-2-oxo-N-phenylacetamide complexes. Spectrochim Acta A Mol Biomol Spectrosc. 2011; 83(1):271-8. DOI: 10.1016/j.saa.2011.08.030. View

15.

do Amaral D, Cavalcanti B, Bezerra D, Ferreira P, Castro R, Sabino J . Docking, synthesis and antiproliferative activity of N-acylhydrazone derivatives designed as combretastatin A4 analogues. PLoS One. 2014; 9(3):e85380. PMC: 3948622. DOI: 10.1371/journal.pone.0085380. View

16.

Fan C, Su H, Zhao J, Zhao B, Zhang S, Miao J . A novel copper complex of salicylaldehyde pyrazole hydrazone induces apoptosis through up-regulating integrin beta4 in H322 lung carcinoma cells. Eur J Med Chem. 2010; 45(4):1438-46. DOI: 10.1016/j.ejmech.2009.12.048. View

17.

Wada C, Frey R, Ji Z, Curtin M, Garland R, Holms J . Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003; 13(19):3331-5. DOI: 10.1016/s0960-894x(03)00685-1. View

18.

Pernas S, Tolaney S . HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol. 2019; 11:1758835919833519. PMC: 6425535. DOI: 10.1177/1758835919833519. View

19.

Senkardes S, Han M, Kulabas N, Abbak M, Cevik O, Kucukguzel I . Synthesis, molecular docking and evaluation of novel sulfonyl hydrazones as anticancer agents and COX-2 inhibitors. Mol Divers. 2019; 24(3):673-689. DOI: 10.1007/s11030-019-09974-z. View

20.

Almansour N . Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci. 2022; 9:836417. PMC: 8824427. DOI: 10.3389/fmolb.2022.836417. View